Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
...
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to ...
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
- Associated Therapies
- -
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 3686
- Registration Number
- NCT01911364
- Locations
- 🇮🇹
Azienda Ospedaliera Perugia, Perugia, Italy
🇩🇪Institut für klinische Forschung, Hessen, Germany
🇭🇺Csongrád Megyei Mellkasi Betegségek Szakkórháza, Szeged, Hungary
Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT01727024
- Locations
- 🇧🇷
Novartis Investigative Site, São Paulo, SP, Brazil
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
- Conditions
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01715311
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3
- Registration Number
- NCT01708057
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
- Conditions
- Interventions
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1137
- Registration Number
- NCT01696058
- Locations
- 🇺🇸
1222.52.02068 Boehringer Ingelheim Investigational Site, Chesterfield, Missouri, United States
🇺🇸1222.52.02035 Boehringer Ingelheim Investigational Site, Henderson, Nevada, United States
🇺🇸1222.52.02091 Boehringer Ingelheim Investigational Site, Syracuse, New York, United States
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1134
- Registration Number
- NCT01694771
- Locations
- 🇺🇸
1222.51.01079 Boehringer Ingelheim Investigational Site, Tamarac, Florida, United States
🇺🇸1222.51.01076 Boehringer Ingelheim Investigational Site, Austell, Georgia, United States
🇺🇸1222.51.01041 Boehringer Ingelheim Investigational Site, San Diego, California, United States
Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD
- Conditions
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2014-01-08
- Target Recruit Count
- 20
- Registration Number
- NCT01693003
- Locations
- 🇧🇷
Pavilhão Pereira Filho, Porto Alegre, RS, Brazil
Beta Blocker Therapy in Moderate to Severe COPD
- Conditions
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 18
- Registration Number
- NCT01656005
- Locations
- 🇬🇧
Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom
Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 657
- Registration Number
- NCT01613326
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei County, Taiwan
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
- Conditions
- Interventions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1215
- Registration Number
- NCT01610037
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.